Strona główna・Stock List・Natera Inc

Natera Inc

Closed

SectorHealthcare

321.98 21.19

Buy Sell

Overview

Share price change

24h

Current

Min

265.23

Max

321.98

Key metrics
By Trading Economics
Income	-132M -85M
Sales	31M 697M
EPS	-0.6
Profit margin	-12.214
Employees	6,135
EBITDA	-30M -65M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+19.94% upside

Dividends
By Acuity
Next Earnings	5 lis 2026

Market Stats
By TradingEconomics
Market Cap	8.5B 39B
Previous open	300.79
Previous close	321.98

News Sentiment

By Acuity

40%

60%

120 / 340 Ranking in Healthcare

Natera Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sie 2026, 20:03 UTC

Social Media

News

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.

6 sie 2026, 23:02 UTC

Social Media

News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5 sie 2026, 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4 sie 2026, 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3 sie 2026, 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31 lip 2026, 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30 lip 2026, 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

29 lip 2026, 22:02 UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

28 lip 2026, 23:46 UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

27 lip 2026, 19:46 UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

24 lip 2026, 18:46 UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

22 lip 2026, 18:36 UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

21 lip 2026, 18:36 UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

20 lip 2026, 18:16 UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Peer Comparison

Price change

Natera Inc Forecast

Price Target

By TipRanks

19.94% upside

12 Months Forecast

Average 318.29 USD 19.94%

High 375 USD

Low 249 USD

Based on 19 Wall Street analysts offering 12 month price targets forNatera Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Natera Inc - Dist in the past 3 months.

Sentiment

By Acuity

120 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.